A retrospective, single-centre study to compare efficacy and safety of the original and biosimilar adalimumab (ABP-501) molecules molecules on pediatric patients
Latest Information Update: 23 Jun 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatic disorders
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism.